Communiqués Protagonist Therapeutics, Inc.

Actions

PTGX

US74366E1029

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 20/08/2026			Varia. 5j.	Varia. 1 janv.
150,69 ^USD	-2,74%		-0,48%	+72,53%

13/08	Protagonist Therapeutics : un dirigeant cède des actions pour près de 14,9 millions de dollars, selon un document de la SEC	MT
11/08	Les données de Silence Therapeutics sur le divesiran confirment son potentiel de leader du marché, selon Morgan Stanley	MT

Communiqués

18/08	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
05/08	Protagonist Therapeutics: Q2 Earnings Snapshot	AQ
05/08	Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
04/08	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
16/07	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
01/07	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
16/06	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
01/06	Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress	AQ
28/05	Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026	AQ
06/05	Protagonist Therapeutics: Q1 Earnings Snapshot	AQ
06/05	Protagonist Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05/05	Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
28/04	Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration	AQ
16/04	Protagonist Therapeutics Reports Granting of Inducement Awards	AQ
28/03	Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting	AQ
18/03	Protagonist Therapeutics : Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis	PU
26/02	Protagonist Therapeutics: Q4 Earnings Snapshot	AQ
25/02	Protagonist Therapeutics : Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	PU
06/11	Protagonist Therapeutics : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
06/11	Protagonist Therapeutics: Q3 Earnings Snapshot	AQ
21/10/25	Big Pharma Just Put Peptides Back on the Map - Which Players Are Still Under the Radar?	AQ
06/08/25	Protagonist Therapeutics: Q2 Earnings Snapshot	AQ
09/05/25	Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting	AQ
06/05/25	Protagonist Therapeutics: Q1 Earnings Snapshot	AQ
06/05/25	Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update	AQ